Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUMETANIDE vs NIASPAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Niacin (nicotinic acid) reduces hepatic production of VLDL and LDL, and increases HDL by inhibiting diacylglycerol acyltransferase-2 (DGAT2) and reducing hepatic triglyceride synthesis. It also decreases the catabolism of HDL apolipoproteins A-I and A-II.
Edema associated with congestive heart failure, hepatic cirrhosis, and renal disease,Treatment of hypertension (off-label)
Primary dyslipidemia and mixed dyslipidemia as an adjunct to diet,Hypertriglyceridemia in patients at risk of pancreatitis,Reduction of risk of myocardial infarction in patients with hyperlipidemia and history of MI,Secondary prevention of cardiovascular events in combination with statin,Off-label: Prevention of pellagra (niacin deficiency)
0.5-2 mg IV/IM/PO once daily; may repeat every 6-8 hours; max 10 mg/day. Continuous IV infusion: 1 mg loading dose, then 0.5-2 mg/hour.
Starting dose: 500 mg orally once daily at bedtime; after 4 weeks, increase to 1000 mg once daily; then titrate to maintenance dose of 1500-2000 mg once daily; maximum dose: 2000 mg/day.
Terminal elimination half-life is approximately 1-1.5 hours in healthy adults; prolonged to 1.5-3 hours in renal impairment.
Terminal half-life is 20-45 minutes (immediate-release) but due to prolonged release formulation of Niaspan, the half-life is extended to 2-4 hours for total nicotinic acid and 12 hours for nicotinuric acid, allowing once-daily dosing.
Primarily metabolized by the liver via cytochrome P450 (CYP) enzymes, with approximately 50% excreted unchanged in urine.
Primarily hepatic metabolism via two pathways: conjugation with glycine to form nicotinuric acid (major pathway, saturable) and conversion to nicotinamide adenine dinucleotide (NAD). Minor metabolism via oxidation to N-methylnicotinamide and other metabolites.
Primarily renal (approximately 80% as unchanged drug), with minimal biliary/fecal excretion (about 10-20%).
Primarily renal (60-76% as unchanged drug and metabolites). Hepatic metabolism is extensive; less than 2% excreted in feces.
Approximately 95% bound, primarily to albumin.
<20% bound to plasma proteins (mainly albumin). Binding is negligible at therapeutic concentrations.
0.15-0.25 L/kg; indicates limited extravascular distribution, consistent with high protein binding.
Approximately 0.5 L/kg (around 35 L in a 70 kg adult), indicating distribution into total body water.
Oral: approximately 80-100% (mean ~90%), with a first-pass effect of about 10-20%.
Oral (extended-release): ~60-76% due to extensive first-pass metabolism. Bioavailability is dose-dependent and saturable at higher doses.
No specific dose adjustment for GFR >20 m L/min. For GFR 10-20 m L/min: use with caution, dose every 12-24 hours. For GFR <10 m L/min: not recommended due to lack of efficacy.
No specific dose adjustment provided by manufacturer; use with caution in patients with renal impairment; avoid in patients with severe renal impairment or nephrotic syndrome.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Contraindicated in patients with significant or unexplained hepatic dysfunction; use with caution in patients with Child-Pugh class A, avoid in Child-Pugh class B or C.
IV/IM/PO: 0.015-0.1 mg/kg/dose every 6-24 hours; max 10 mg/day. For neonates: 0.01-0.05 mg/kg/dose every 12-24 hours.
Safety and efficacy not established in pediatric patients; not recommended for use.
Start at 0.5 mg once daily; titrate cautiously due to increased sensitivity and risk of electrolyte imbalance and volume depletion.
No specific dose adjustment recommended; monitor for adverse effects such as myopathy and hepatotoxicity; initiate at low end of dosing range.
Bumetanide is a potent diuretic that can lead to profound diuresis with water and electrolyte depletion. Close medical supervision and dose titration are required. Excessive doses can lead to hypovolemia, dehydration, and circulatory collapse.
No FDA black box warning.
Monitor fluid and electrolyte balance closely,Risk of ototoxicity, especially at high doses or with rapid infusion,May cause hyperuricemia and precipitate gout attacks,Can increase risk of digitalis toxicity due to hypokalemia
Hepatotoxicity: elevated liver enzymes, rare severe hepatotoxicity; avoid in patients with active liver disease,Flushing: prostaglandin-mediated, can be reduced by taking aspirin or starting with low doses,Hyperglycemia: may increase blood glucose, use with caution in diabetic patients,Hyperuricemia: may precipitate gout, monitor uric acid,Gastrointestinal effects: can cause peptic ulcer, use caution with history of GI bleeding,Cardiovascular: may cause hypotension, especially with concurrent use of antihypertensives
Anuria,Severe electrolyte depletion,Hepatic coma or pre-coma,Hypersensitivity to bumetanide or sulfonamides
Active liver disease or unexplained transaminase elevations,Active peptic ulcer disease,Arterial bleeding,Hypersensitivity to niacin or any component of the formulation
No specific food restrictions, but limit salt intake to help control edema and hypertension. Avoid excessive intake of black licorice (can worsen hypokalemia). Grapefruit juice may not significantly interact, but caution with any electrolyte-altering foods. Maintain adequate fluid intake unless fluid restriction is advised by your doctor. Foods high in potassium (bananas, oranges, spinach) may be recommended if hypokalemia occurs; consult provider for individual needs.
Avoid alcohol, hot beverages, and spicy foods near dose time as they can worsen flushing. Take with a low-fat snack (e.g., apple, rice cakes) to reduce gastrointestinal upset and flushing. Avoid high-fat meals which may increase risk of flushing. Grapefruit juice has no significant interaction but other fruit juices have not been studied; advise moderate intake.
Bumetanide crosses the placenta. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Risk of electrolyte imbalances and hypovolemia in the fetus; possible oligohydramnios. Avoid use during pregnancy unless benefits outweigh risks.
Niacin (NIASPAN) is classified as FDA Pregnancy Category C. Animal studies have shown adverse effects at high doses, but there are no adequate and well-controlled studies in pregnant women. Niacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. There is no evidence of teratogenicity in humans at recommended doses, but high doses may cause fetal harm.
Bumetanide is excreted into human milk in small amounts (M/P ratio not determined). Due to potential for diuresis in the infant, use with caution, especially in neonates. Consider alternative agents with more safety data.
Niacin is excreted in human breast milk in amounts that are likely comparable to maternal plasma levels. The milk-to-plasma (M/P) ratio for niacin is approximately 1.0. The American Academy of Pediatrics considers niacin compatible with breastfeeding at usual dietary intakes, but high pharmacological doses should be avoided due to potential adverse effects in the infant, such as flushing and gastrointestinal disturbances.
Pregnancy may increase volume of distribution and renal clearance, potentially requiring higher doses. However, starting dose is generally unchanged; titration based on response and tolerability. Monitor for hypokalemia and hypovolemia.
No specific dose adjustments are recommended for niacin during pregnancy due to lack of data on pharmacokinetic changes. However, doses should be kept at the lowest effective level and used only when clearly needed. There is no evidence that pregnancy alters niacin clearance or requires dose modification.
Bumetanide is a potent loop diuretic with rapid onset and short duration. Oral bioavailability is ~80% with minimal first-pass metabolism. Onset of diuresis within 30-60 minutes, peak at 1-2 hours, duration 4-6 hours. For acute pulmonary edema, intravenous bumetanide can be given 0.5-1 mg; onset within minutes. Monitor electrolytes especially potassium, magnesium, and calcium due to increased excretion. May cause ototoxicity, especially with rapid IV administration or concurrent aminoglycosides. Use with caution in sulfonamide allergy (cross-sensitivity). In renal impairment, bumetanide may be less effective due to reduced tubular secretion; higher doses may be needed. Combine with thiazides for sequential nephron blockade in resistant edema.
Niacin extended-release (NIASPAN) causes flushing, which can be mitigated by taking aspirin 30 minutes before dosing, avoiding alcohol and hot beverages at time of dosing, and initiating at low dose with gradual titration. Liver function tests must be monitored; elevation >3x ULN requires discontinuation. NIASPAN can exacerbate gout by increasing uric acid levels; check uric acid at baseline and periodically. Use with caution in diabetes as it may increase glucose levels. Avoid in patients with active liver disease, unexplained transaminase elevations, or peptic ulcer disease.
Take bumetanide exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Do not skip doses or double up on missed doses; if you miss a dose, take it as soon as you remember unless it is almost time for the next dose.,This medication can cause dehydration and electrolyte imbalances; notify your doctor if you experience excessive thirst, dry mouth, weakness, muscle cramps, or irregular heartbeat.,Avoid alcohol and over-the-counter medications, especially NSAIDs (ibuprofen, naproxen) unless approved by your doctor, as they may reduce bumetanide's effectiveness and increase kidney risk.,Stand up slowly from sitting or lying to prevent dizziness from low blood pressure.,Monitor your weight daily and report rapid weight gain or loss to your healthcare provider.
Take NIASPAN at bedtime with a low-fat snack to reduce flushing.,Do not take on an empty stomach; avoid alcohol and hot drinks near dose time.,Flushing may occur but usually decreases over weeks; can take aspirin 30 minutes prior to dose.,Do not miss doses; if a dose is missed, do not double up the next day.,Common side effects include flushing, itching, and tingling; report severe or persistent effects.,Your doctor will monitor blood glucose, uric acid, and liver function regularly.,Do not substitute with other niacin preparations without doctor approval.
"Concurrent use of bumetanide, a loop diuretic, and allopurinol, a xanthine oxidase inhibitor, may increase the risk of allopurinol hypersensitivity reactions, including Stevens-Johnson syndrome and acute gout flares. This interaction is thought to result from bumetanide-induced volume depletion and reduced renal clearance of oxypurinol, the active metabolite of allopurinol, leading to elevated serum oxypurinol levels and enhanced toxicity. Clinically, patients may present with rash, fever, eosinophilia, or acute gouty arthritis, particularly in those with renal impairment."
"Fenbufen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits renal prostaglandin synthesis, which can reduce the efficacy of loop diuretics like bumetanide by blunting the diuretic-induced increase in renal blood flow and sodium excretion. This pharmacodynamic antagonism may result in diminished diuresis and natriuresis, potentially exacerbating fluid overload in patients with heart failure or hypertension. Clinically, this interaction may lead to suboptimal blood pressure control or worsening edema if the combination is used without dose adjustment."
"Concurrent administration of apomorphine, a dopamine agonist used for Parkinson's disease, with bumetanide, a loop diuretic, may lead to an increased risk of adverse effects, particularly hypotension and syncope. Apomorphine is known to cause orthostatic hypotension due to its vasodilatory and dopaminergic effects, which can be potentiated by bumetanide-induced volume depletion and electrolyte disturbances. This interaction can result in profound blood pressure drops, dizziness, and potential falls, especially in elderly patients or those with already compromised cardiovascular status."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUMETANIDE vs NIASPAN, answered by our medical review team.
BUMETANIDE is a Loop Diuretic that works by Inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.. NIASPAN is a Antilipemic agent that works by Niacin (nicotinic acid) reduces hepatic production of VLDL and LDL, and increases HDL by inhibiting diacylglycerol acyltransferase-2 (DGAT2) and reducing hepatic triglyceride synthesis. It also decreases the catabolism of HDL apolipoproteins A-I and A-II.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUMETANIDE and NIASPAN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUMETANIDE is: 0.5-2 mg IV/IM/PO once daily; may repeat every 6-8 hours; max 10 mg/day. Continuous IV infusion: 1 mg loading dose, then 0.5-2 mg/hour.. The standard adult dose of NIASPAN is: Starting dose: 500 mg orally once daily at bedtime; after 4 weeks, increase to 1000 mg once daily; then titrate to maintenance dose of 1500-2000 mg once daily; maximum dose: 2000 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUMETANIDE and NIASPAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUMETANIDE is classified as Category A/B. Bumetanide crosses the placenta. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Risk o. NIASPAN is classified as Category C. Niacin (NIASPAN) is classified as FDA Pregnancy Category C. Animal studies have shown adverse effects at high doses, but there are no adequate and well-controlled studies in pregna. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.